The efficacy and safety of quinupristin/dalfopristin for the treatment of infections caused by vancomycin-resistant Enterococcus faecium

Journal of Antimicrobial Chemotherapy

Volumn 44, Issue 2, 1999, Pages 251-261

  Moellering, R C ^a   Linden, P K ^b   Reinhardt, J ^c   Blumberg, E A ^d   Bompart, F ^e   Talbot, G H ^f  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c CHRISTIANA CARE HEALTH SYSTEM   (United States)

^d ALLEGHENY UNIVERSITY HOSPITALS   (United States)

^e SANOFI   (France)

^f NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; DALFOPRISTIN PLUS QUINUPRISTIN; VANCOMYCIN;

ABDOMINAL INFECTION; ADOLESCENT; ADULT; AGED; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTHRALGIA; ARTICLE; ARTIFICIAL VENTILATION; ASTHENIA; BACTEREMIA; CANCER; CATHETER INFECTION; CHILD; CHRONIC LIVER DISEASE; DIABETES MELLITUS; DIALYSIS; DRUG EFFICACY; DRUG SAFETY; ENTEROCOCCUS FAECIUM; FEMALE; HUMAN; INFANT; INTRAVENOUS DRUG ADMINISTRATION; LAPAROTOMY; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MYALGIA; NAUSEA; NEWBORN; ORGAN TRANSPLANTATION; PAIN; RASH; SIDE EFFECT; SKIN INFECTION; STREPTOCOCCUS INFECTION; TIME; TREATMENT OUTCOME; URINARY TRACT INFECTION; VOMITING;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CHILD; CHILD, PRESCHOOL; ENTEROCOCCUS FAECIUM; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; INFANT; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PROSPECTIVE STUDIES; TREATMENT OUTCOME; VANCOMYCIN RESISTANCE; VIRGINIAMYCIN;

EID: 0032795631     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/44.2.251     Document Type: Article

References (53)

1. Leclercq, R., Derlot, E., Duval, J. & Courvalin, P. (1988). Plasmidmediated resistance to vancomycin and teicoplanin in Enterococcus faecium. New England Journal of Medicine 319, 157-61.
2. Gaynes, R. & Edwards, J., The National Nosocomial Infection Surveillance (NNIS) System. (1996). Nosocomial vancomycin-resistant enterococci in the United States. 1989-1995. The first 1000 isolates. Infection Control Hospital Epidemiology 17, 18.
3. Eng, R. H., Ng, K. & Smith, S. M. (1993). Susceptibility of resistant Enterococcus faecium to unusual antibiotics. Journal of Antimicrobial Chemotherapy 31, 609-10.
4. Freeman, C., Robinson, A., Cooper, B., Mazens Sullivan, M., Quintiliani, R. & Nightingale, C. (1995). In vitro antimicrobial susceptibility of glycopeptide-resistant enterococci. Diagnostic Microbiology and Infectious Disease 21, 47-50.
5. Traub, W. H., Leonhard, B. & Bauer, D. (1993). Enterococcus faecium: in-vitro activity of antimicrobial drugs, singly and combined, with and without defibrinated human blood, against multiple-antibiotic-resistant strains. Chemotherapy 39, 254-64.
6. Leclercq, R., Bingen, E., Su, Q. H., Lambert-Zechovski, N., Courvalin, P. & Duval, J. (1991). Effects of combination of β-lactams, daptomycin, gentamicin, and glycopeptides against glycopeptide-resistant enterococci. Antimicrobial Agents and Chemotherapy 35, 92-98.
7. Hayden, M. K., Koenig, G. I. & Trenholme, G. M. (1994). Bactericidal activities of antibiotics against vancomycin-resistant Enterococcus faecium blood isolates and synergistic activities of combinations. Antimicrobial Agents and Chemotherapy 38, 1225-9.
8. Tucker, L., Peterson, L., Noskin, G., Cooper, I. & Reisberg, B. (1993). Activity of 32 antimicrobial agents alone and in combination against high-level vancomycin-resistant Enterococcus faecium. In Program and Abstracts of the Thirty-Third Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, LA, 1993. Abstract 1061, p. 313. American Society for Microbiology, Washington, DC.
9. Norris, A. H., Reilly, J. P., Edelstein, P. H., Brennan, P. J. & Schuster, M. G. (1995). Chloramphenicol for the treatment of vancomycin-resistant enterococcal infections. Clinical Infectious Diseases 20, 1137-44.
10. Lukashok, S. A. & Casadevall, A. (1997). Persistent vancomycin-resistant Enterococcus faecium bacteremia. Infectous Diseases in Clinical Practice 6, 250-5.
11. Moellering, R. C. (1997). The Enterococcus: Paradigm of the problematic pathogen. In Plenary Session Presentation of the Twentieth International Congress of Chemotherapy, Sydney, Australia, 1997. p. 119. International Society of Chemotherapy.
12. Feldman, R. J., Paul, S. M., Silber, J. L., Cody, R. P., Noveck, H. & Weinstein, M. P. (1996). An analysis of treatment of patients with vancomycin-resistant enterococcal bacteremia. Infectious Diseases in Clinical Practice 5, 440-5.
13. Dominguez, E. R., Diaz, A. & Greene, J. N. (1996). Successful treatment of vancomycin-resistant enterococcal bacteremia using combination antibiotic therapy. In program and Abstracts of the Infectious Disease Society of America Thirty-Fourth Annual Meeting, New Orleans, LA, 1996. Abstract 169, p. 67. Infectious Disease Society of America, USA.
14. Mekonen, E., Noskin, G. A., Hacek, D., Dressel, D. & Peterson, L. R. et al. (1995). Successful therapy of vancomycin-resistant Enterococcus faecium (VREfe) bacteremia with continuous infusion ampicillin-sulbactam at 30 grams per day combined with intermittent gentamicin. Journal of Investigative Medicine 43, Suppl. 3, 485A.
15. Stosor, V., Peterson, L. R., Postelnick, M. & Noskin, G. A. Therapy of vancomycin-resistant Enterococcus faecium sepsis: a novel strategy. In Program and Abstracts of the Infectious Disease Society of America Thirty-Fourth Annual Meeting, New Orleans, LA, 1996. Abstract 170, p. 67. Infectious Disease Society of America, USA.
16. Montecalvo, M. A., Horowitz, H., Wormser, G. P., Seiter, K. & Carbonaro, C. A. (1995). Effect of novobiocin-containing antimicrobial regimens on infection and colonization with vancomycin-resistant Enterococcus faecium. Antimicrobial Agents and Chemotherapy 39, 794.
17. Linden, P., Pasculle, A. W., Manez, R., Silverman, D., Kramer, D. J. & Kusne, S. (1993). Utilization of novobiocin and ciprofloxacin for the treatment of serious infections due to vancomycin-resistant Enterococcus faecium. In Program and Abstracts of the Thirty-Third Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, LA, 1993. Abstract 1027, p. 307. American Society for Microbiology, Washington, DC.
18. Murray, B. E. (1997). Vancomycin-resistant enterococci. American Journal of Medicine 102, 284-93.
19. Cocito, C., Di Giambattista, M., Nyssen, E. & Vannuffel, P. (1997). Inhibition of protein synthesis by streptogramins and related antibiotics. Journal of Antimicrobial Chemotherapy 39, Suppl. A, 7-13.
20. Baquero, F. (1997). Gram-positive resistance: challenge for the development of new antibiotics. Journal of Antimicrobial Chemotherapy 39, Suppl. A, 1-6.
21. Caron, F., Gold, H. S., Wennersten, C. B., Farris, M. G., Moellering, R. C. & Eliopoulos, G. M. (1997). Influence of erythromycin resistance, inoculum growth phase, and incubation time on assessment of the bactericidal activity of RP 59500 (quinupristin/ dalfopristin) against vancomycin-resistant Enterococcus faecium. Antimicrobial Agents and Chemotherapy 41, 2749-53.
22. Beam, T. R., Gilbert, D. N. & Kunin, C. M. (1992). General guidelines for the clinical evaluation of anti-infective drug products. Infectious Diseases Society of America and the Food and Drug Administration. Clinical Infectious Diseases 15, Suppl. 1, S5-S32.
23. European Society of Clinical Microbiology and Infectious Diseases. (1993). European Guidelines for the Clinical Evaluation of Anti-Infective Drug Products, 1993.
24. Knaus, W. A., Wagner, D. P., Draper, E. A., Zimmerman, J. E., Bergner, M., Bastos, P. G. et al. (1991). The APACHE III prognostic system. Risk prediction of hospital mortality for critically ill hospitalized adults. Chest 100, 1619-36.
25. Facklam, R. R. & Collins, M. D. (1989). Identification of Enterococcus species isolated from human infections by a conventional test scheme. Journal of Clinical Microbiology 27, 731-4.
26. Cartwright, C. P., Stock, F., Fahle, G. A. & Gill, V. J. (1995). Comparison of pigment production and motility tests with PCR for reliable identification of intrinsically vancomycin-resistant enterococci. Journal of Clinical Microbiology 33, 1931-3.
27. Rice, L. B., Eliopoulos, G. M., Wennersten, C., Goldmann, D., Jacoby, G. A. & Moellering R. C. (1991). Chromosomally mediated β-lactamase production and gentamicin resistance in Enterococcus faecalis. Antimicrobial Agents and Chemotherapy 35,272-6.
28. Coque, T. M. & Murray, B. E. (1995). Identification of Enterococcus faecalis strains by DNA hybridization and pulsed-field gel electrophoresis. Journal of Clinical Microbiology 33, 3368-9.
29. Costa, Y., Galimand, M., Leclerzq, R., Duval, J. & Courvalin, P. (1993). Characterization of the chromosomal aac(6′)-li gene specific for Enterococcus faecum. Antimicrobial Agents and Chemotherapy 37, 1896-903.
30. Handwerger, S., Pucci, M. J. & Kolokathis, A. (1990). Vancomycin resistance is encoded on a pheromone response plasmid in Enterococcus faecum 228. Antimicrobial Agents and Chemotherapy 34, 358-60.
31. Gold, H. S., Ünal, S., Cercenado, E., Thauvin-Eliopoulos, C., Eliopoulos, G. M., Wennersten, C. B. et al. (1993). A gene conferring resistance to vancomycin but not teicoplanin in isolates of Enterococcus faecalis and Enterococcus faecium demonstrates homology with vanB, vanA, and vanC genes of enterocococci. Antimicrobial Agents and Chemotherapy 37, 1604-9.
32. National Committee for Clinical Laboratory Standards. (1993). Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically-Third edition: Approved Standard M7-A3 NCCLS, Wayne, PA.
33. Free, L. & Sahm, D. F. (1995). Investigation of the reformulated Remel Synergy Quad plate for detection of high-level aminoglycoside and vancomycin resistance among enterococci. Journal of Clinical Microbiology 33, 1643-5.
34. Neter, J., Wasserman, W. & Kutner, M. H. (1989). Applied Linear Regression Models, 2nd edn. Richard Irwin Inc, Homewood, IL.
35. 36. Messick, C. R. & Pendland, S. L. (1997). In vitro activity of chloramphenicol alone and in combination with vancomycin, ampicillin, or RP 59500 (quinupristin/dalfopristin) against vancomycin-resistant enterococci. Diagnostic Microbiology and Infectious Disease 29, 203-5.
36. Aeschlimann, J. R., Zervos, M. J. & Rybak, M. J. (1998). Treatment of vancomycin-resistant Enterococcus faecium with RP 59500 (quinupristin-dalfopristin) administered by intermittent or continuous infusion, alone or in combination with doxycycline, in an in vitro pharmacodynamic infection model with simulated endocardial vegetations. Antimicrobial Agents and Chemotherapy 42, 2710-7.
37. Linden, P. K., Pasculle, A. W., McDevitt, D. & Kramer, D. J. (1997). Effect of quinupristin/dalfopristin on the outcome of vancomycin-resistant Enterococcus faecium bacteremia: comparison with a control cohort. Journal of Antimicrobial Chemotherapy 39, Suppl. A, 145-51.
38. Pocock, S. J. (1976). The combination of randomized and historical controls in clinical trials. Journal of Chronic Diseases 29, 175-88.
39. Lai, K. K. (1996). Treatment of vancomycin-resistant Enterococcus faecium infections. Archives of Internal Medicine 156, 2579-84.
40. Moellering, R. C. (1991). The Garrod Lecture. The enterococcus: a classic example of the impact of antimicrobial resistance on therapeutic options. Journal of Antimicrobial Chemotherapy 28, 1-12.
41. Edmond, M. B., Ober, J. F., Dawson, J. D., Weinbaum, D. L. & Wenzel, R. P. (1996). Vancomycin-resistant enterococcal bacteremia: natural history and attributable mortality. Clinical Infectious Diseases 23, 1234-9.
42. Shay, D. K., Maloney, S. A., Montecalvo, M., Banerjee, S., Wormser, G. P., Arduino, M. J. et al. (1995). Epidemiology and mortality risk of vancomycin-resistant enterococcal bloodstream infections. Journal of Infectious Diseases 172, 993-1000.
43. Tornieport, N. G., Roberts, R. B., John, J., Hafner, A. & Riley, L. W. (1996). Risk factors associated with vancomycin-resistant Enterococcus faecium infection or colonization in 145 matched case patients and control patients. Clinical Infectious Diseases 23, 767-72.
44. Papanicolaou, G. A., Meyers, B. R., Meyers, J., Mendelson, M. H., Lou, W., Emre, S. et al. (1996). Nosocomial infections with vancomycin-resistant Enterococcus faecium in liver transplant recipients: risk factors for acquisition and mortality. Clinical Infectious Diseases 23, 760-6.
45. Chow, J. W., Donabedian, S. M. & Zervos, M. J. (1997). Emergence of increased resistance to quinupristin/dalfopristin during therapy for Enterococcus faecium bacteremia. Clinical Infectious Diseases 24, 90-1.
46. Chow, J. W., Davidson, A., Sanford, E. & Zervos, M. J. (1997). Superinfection with Enterococcus faecalis during quinupristin/ dalfopristin therapy. Clinical Infectious Diseases 24, 91-2.
47. Talbot, G. H. & Zhu, G. R. (1998). Characterization of arthralgia/ myalgia associated with quinupristin/dalfopristin. In Abstract and Posters of the Infectious Disease Society of America Thirty-Sixth Annual Meeting, 1998. Abstract 53, p. 84. Infectious Disease Society of America, USA.
48. Bompart, F., Dorr, M. B., Bekele, T., Barrier, S., Rey, J. & Vassereau, C. et al. (1997). Overview of the safety and tolerability of quinupristin/dalfopristin (Synercid, RP 59500) in the global development program. In Abstract and Posters of the Twentieth International Congress of Chemotherapy, Sydney, Australia, 1997. Abstract 846. International Society of Chemotherapy.
49. Linden, P. K., Talbot, G. H. & Bompart, F. (1998). Liver histopathology in liver transplant recipients with hyperbilirubinemia during quinupristin/dalfopristin therapy. In The Fourth International Conference on the Macrolides, Azalides, Streptogramins and Ketolides, Barcelona, Spain 1998. The Fourth International Conference on the Macrolides, Azalides, Streptogramins and Ketolides.
50. Moellering, R. C. (1999). A novel antimicrobial agent joins the battle against resistant bacteria. Annals of Internal Medicine 130, 155-7.
51. Dresser, L. D. & Rybak, M. J. (1998). The pharmacologic and bacteriologic properties of oxazolidinones, a new class of synthetic antimicrobials. Pharmacotherapy 18, 456-62.
52. Wise, R., Andrews, J. M., Boswell, F. J. & Ashby, J. P. (1998). The in-vitro activity of linezolid (U-100766) and tentative breakpoints. Journal of Antimicrobial Chemotherapy 42, 721-8.
53. Landman, D. & Quale, J. M. (1997). Management of infections due to resistant enterococci: a review of therapeutic options. Journal of Antimicrobial Chemotherapy 40, 161-70.